Related Experiment Video
Updated: Nov 23, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Lipid control and its associated factors among patients with dyslipidaemia in Jordan
Anan S Jarab1, Eman A Alefishat2,3,4, Walid Al-Qerem5
1Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan.
Insights
Poor lipid control is common in Jordanian dyslipidaemia patients, especially smokers with atherosclerotic cardiovascular disease (ASCVD). Improving medication adherence and simplifying regimens are key to better lipid management and outcomes.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Lipid control is crucial for managing atherosclerotic cardiovascular disease (ASCVD).
- Factors contributing to poor lipid control in dyslipidaemia patients remain under-researched.
Purpose of the Study:
- To investigate variables associated with poor lipid control in Jordanian dyslipidaemia patients.
- To identify predictors of dyslipidaemia control in a clinical setting.
Main Methods:
- Retrospective chart review of 228 dyslipidaemia patients in Jordan.
- Collected socio-demographics, disease/medication data, and lipid profiles.
- Assessed medication adherence and beliefs; used AHA guidelines for control classification.
- Stepwise logistic regression identified independent predictors of lipid control.
Main Results:
- 61% of patients had uncontrolled lipid profiles; 60.1% had ASCVD.
- Increased perceived medication necessity correlated with better control (OR=1.14).
- Active smoking (OR=0.42), low adherence (OR=0.0.8), and ASCVD presence (OR=0.24) were linked to poor control.
Conclusions:
- Significant potential exists to improve lipid control in Jordanian dyslipidaemia patients.
- Interventions should focus on enhancing medication adherence, emphasizing necessity, and simplifying regimens.
- Targeted strategies for smokers and ASCVD patients are essential for improved lipid management and health outcomes.
Background:
Lipid control represents a cornerstone in the management of atherosclerotic cardiovascular disease (ASCVD). Nevertheless, little research has explored the factors associated with poor lipid control in patients with dyslipidaemia.
Objective:
The study aim was to investigate the variables associated with poor lipid control among patients with dyslipidaemia in Jordan.
Method:
In addition to socio-demographics, disease and medication-related variables, lipid profile including total cholesterol, LDL-C, HDL-C and triglyceride and other biomedical variables were collected for patients diagnosed with dyslipidaemia using hospital medical charts at three major outpatient clinics in Jordan. The validated 4-item medication adherence scale and the beliefs about medications questionnaire were used to evaluate medication adherence and medication beliefs among the study participants. The participants were classified to have controlled and uncontrolled dyslipidaemia using recent AHA guidelines. A stepwise forward conditional binary regression was conducted to explore the variables significantly and independently associated with dyslipidaemia control. A P-value of < .05 was considered statistically significant.
Results:
A total of 228 patients participated in the study. Most of the study participants (61%) were classified to have uncontrolled lipid profile and 60.1% of them were found to have ASCVD. Regression analysis revealed that increased necessity for dyslipidaemia medications increased the odds of dyslipidaemia control (OR = 1.14), whereas active smoking (OR = 0.42), low medication adherence (OR = 0.0.8) and the presence of ASCVD (odd ratio = 0.24) were significantly associated with poor dyslipidaemia control.
Conclusion:
Lipid profile has considerable scope for improvement in patients with dyslipidaemia in Jordan. Improving medication adherence by emphasising on medication necessity and simplifying the prescribed dosage regimen, particularly in smoking patients and those who have ASCVD, should be particularly considered in future clinical pharmacy service programmes aim at improving lipid control and health outcomes in patients with dyslipidaemia.
Related Concept Videos
Atherosclerosis III: Management
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Lipids: Dietary Sources and Requirements
Cholesterol: Significance and Regulation
Considering cholesterol and...
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
